These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 12750842)

  • 1. Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group study.
    Soo RA; Lim HL; Wang LZ; Lee HS; Millward MJ; Tok LT; Lee SC; Lehnert M; Goh BC
    Cancer Chemother Pharmacol; 2003 Aug; 52(2):153-8. PubMed ID: 12750842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of gemcitabine and carboplatin in metastatic non-small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie Study.
    Thomas P; Robinet G; Ferri-Dessens RM; Léna H; Gouva S; Vernejoux JM; Kleisbauer JP
    Lung Cancer; 2002 May; 36(2):191-8. PubMed ID: 11955654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer.
    Soo RA; Wang LZ; Tham LS; Yong WP; Boyer M; Lim HL; Lee HS; Millward M; Liang S; Beale P; Lee SC; Goh BC
    Ann Oncol; 2006 Jul; 17(7):1128-33. PubMed ID: 16670205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma.
    Gajra A; Mehdi SA; Kirshner J; Newman N; Graziano SL
    Lung Cancer; 2001 May; 32(2):189-96. PubMed ID: 11325490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RTOG 0017: a phase I trial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy ("ping-pong trial") followed by adjuvant chemotherapy for patients with favorable prognosis inoperable stage IIIA/B non-small cell lung cancer.
    Choy H; Jain AK; Moughan J; Curran W; Whipple G; Demas WF; Ettinger DS
    J Thorac Oncol; 2009 Jan; 4(1):80-6. PubMed ID: 19096311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biweekly Carboplatin Plus Gemcitabine as First-Line Treatment of Elderly Patients With Advanced Squamous Non-Small-cell Lung Cancer: A Multicenter Phase I-II Trial by the Hellenic Oncology Research Group.
    Karampeazis A; Vamvakas L; Kentepozidis N; Polyzos A; Chandrinos V; Rigas G; Christofyllakis C; Kotsakis A; Hatzidaki D; Pallis AG; Georgoulias V
    Clin Lung Cancer; 2016 Nov; 17(6):543-549. PubMed ID: 27397849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
    Gray HJ; Bell-McGuinn K; Fleming GF; Cristea M; Xiong H; Sullivan D; Luo Y; McKee MD; Munasinghe W; Martin LP
    Gynecol Oncol; 2018 Mar; 148(3):507-514. PubMed ID: 29352572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer.
    Kurata T; Tamura K; Yamamoto N; Nogami T; Satoh T; Kaneda H; Nakagawa K; Fukuoka M
    Br J Cancer; 2004 Jun; 90(11):2092-6. PubMed ID: 15150564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer.
    Iaffaioli RV; Tortoriello A; Facchini G; Caponigro F; Gentile M; Marzano N; Gravina A; Dimitri P; Costagliola G; Ferraro A; Ferrante G; De Marino V; Illiano A
    J Clin Oncol; 1999 Mar; 17(3):921-6. PubMed ID: 10071285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
    Wang LR; Huang MZ; Zhang GB; Xu N; Wu XH
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):601-7. PubMed ID: 17549479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine in brief versus prolonged low-dose infusion, both combined with carboplatin for advanced non-small cell lung cancer.
    Beniwal SK; Patel KM; Shukla S; Parikh BJ; Shah S; Patel A
    Indian J Cancer; 2012; 49(2):202-8. PubMed ID: 23107971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
    Davies AM; Ruel C; Lara PN; Lau DH; Gumerlock PH; Bold R; Shibata S; Lenz HJ; Schenkein DP; Gandara DR
    J Thorac Oncol; 2008 Jan; 3(1):68-74. PubMed ID: 18166843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer.
    Xu N; Shen P; Zhang XC; Yu LF; Bao HY; Shi GM; Huang S; Chen J; Mou HB; Fang WJ
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):1-7. PubMed ID: 16614849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer.
    Wang L; Wu X; Huang M; Cai J; Xu N; Liu J
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):211-8. PubMed ID: 17124596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial.
    Zatloukal P; Petruzelka L; Zemanová M; Kolek V; Skricková J; Pesek M; Fojtů H; Grygárková I; Sixtová D; Roubec J; Horenková E; Havel L; Průsa P; Nováková L; Skácel T; Kůta M
    Lung Cancer; 2003 Sep; 41(3):321-31. PubMed ID: 12928123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of low-dose gemcitabine in 6-hour infusion and carboplatin is a favorable option for patients in poor performance status with advanced non-small cell lung cancer.
    Wu ZY; Guan HH; Lin ZX; Yang HK; Zhou L; Cai QC
    J Chemother; 2014 Oct; 26(5):306-11. PubMed ID: 24075685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized phase II trial using two different treatment schedules of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
    Masters GA; Argiris AE; Hahn EA; Beck JT; Rausch PG; Ye Z; Monberg MJ; Bloss LP; Curiel RE; Obasaju CK
    J Thorac Oncol; 2006 Jan; 1(1):19-24. PubMed ID: 17409822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of gemcitabine and carboplatin in non-small cell lung cancer.
    Carmichael J; Allerheiligen S; Walling J
    Semin Oncol; 1996 Oct; 23(5 Suppl 10):55-9. PubMed ID: 8893883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma.
    Faivre S; Le Chevalier T; Monnerat C; Lokiec F; Novello S; Taieb J; Pautier P; Lhommé C; Ruffié P; Kayitalire L; Armand JP; Raymond E
    Ann Oncol; 2002 Sep; 13(9):1479-89. PubMed ID: 12196375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.
    Leijen S; Veltkamp SA; Huitema AD; van Werkhoven E; Beijnen JH; Schellens JH
    Gynecol Oncol; 2013 Sep; 130(3):511-7. PubMed ID: 23665458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.